Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans.
about
Plasmodium falciparum erythrocyte invasion: combining function with immune evasionProduction of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemBinding of Plasmodium falciparum Merozoite Surface Proteins DBLMSP and DBLMSP2 to Human Immunoglobulin M Is Conserved among Broadly Diverged Sequence VariantsStructural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPAHost-Parasite Interactions in Human Malaria: Clinical Implications of Basic ResearchSubclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes.A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine designRecent advances in recombinant protein-based malaria vaccines.Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan populationProgress and prospects for blood-stage malaria vaccinesThe association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria.Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.Host-parasite interactions that guide red blood cell invasion by malaria parasites.Genetic evidence for erythrocyte receptor glycophorin B expression levels defining a dominant Plasmodium falciparum invasion pathway into human erythrocytes.Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates.Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.Naturally Acquired Human Antibodies Against Reticulocyte-Binding Domains of Plasmodium vivax Proteins, PvRBP2c and PvRBP1a, Exhibit Binding-Inhibitory Activity.Host Cell Tropism and Adaptation of Blood-Stage Malaria Parasites: Challenges for Malaria Elimination.Implications from predicted B-cell and T-cell epitopes of Plasmodium falciparum merozoite proteins EBA175-RII and Rh5.Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria.Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cellsFunctional Characterization of Plasmodium falciparum Surface-Related Antigen as a Potential Blood-Stage Vaccine Target
P2860
Q21131363-E8279FFC-7B60-4F6D-8252-988127A12FA4Q26700012-24221F7A-62FF-4860-9A88-591AF7223309Q27974543-33D408AD-0235-404D-8A48-DFBF0E363802Q30049152-D26C7A22-7F47-4748-BC3D-55C558AB54C8Q33701044-763F8BCD-4FD9-43BD-8EA3-BD906849A2DBQ34515219-F4BD27E8-DA61-43F8-8DC2-FC98BEB16659Q34978590-E539A3ED-0F50-4827-A689-A971F3E9F322Q35167000-784E95CC-8F57-4D23-AD94-AE70952E7C2CQ35227478-43222EE9-EE23-4ACA-B418-77D9FD287188Q35887367-543A7C91-C1DD-4D79-B7FA-DFDA2C70F439Q36394182-73199A6B-5F9C-4C16-BD25-7E19852CEE0EQ36875789-7B6BD25E-6FD4-49A3-9F4D-369C5070DE7BQ37025030-1DF82D69-BF64-48E1-B18F-B566B5EC6FF8Q37239883-6E18EF09-C9A1-493F-B81F-099992127AD8Q37582331-DCBCE59C-6251-46C7-95DE-65044BC08387Q38376500-F7E45DE0-5DFF-48CE-B4B6-A96E0093C14AQ38650817-0F4404B8-0017-41E3-B928-B8ADDE9AA388Q38672088-F444CB76-D0AC-4177-B090-DAC7C9A60FD0Q38718229-18165080-3BBD-474B-A877-ECD3D6F94CEFQ38853118-7112D62D-54FC-4272-B708-08F6EADEB104Q40327737-418E4592-6E78-43FF-9995-7EB40D7BAFDEQ42114064-BA7861A6-B9B0-4A14-89C2-DE7833ABC256Q55267077-BC45A382-2EAF-4DE4-97C8-D7DDD48AE99CQ56342201-55C7EA69-B0A1-4D34-BB2C-DF90D341B5F4Q56357802-89FED6FB-B54C-48CB-94C3-6DE6DA6118E6
P2860
Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detectable levels of invasion-inhibiting antibodies in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@en
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@nl
type
label
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@en
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@nl
prefLabel
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@en
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@nl
P2093
P2860
P356
P1476
Plasmodium falciparum merozoit ...... hibiting antibodies in humans.
@en
P2093
Ambroise D Ahouidi
Saurabh D Patel
Stephen C Harrison
Tandakha N Dieye
P2860
P304
P356
10.1093/INFDIS/JIT385
P407
P577
2013-07-31T00:00:00Z